Skip to main content

Table 1 Baseline characteristics of the study population

From: Strain parameters for predicting the prognosis of non‐ischemic dilated cardiomyopathy using cardiovascular magnetic resonance tissue feature tracking

  Healthy control subjects
(n = 25)
Recovered NDCM
(n = 21)
Unrecovered NDCM
(n = 58)
P value
Age, y 48 ± 11 46 ± 14 53 ± 16 0.064
Male, % 18 (72%) 19 (90%) 42 (72%) 0.219
Systolic BP, mmHg 120 ± 11 124 ± 19 122 ± 16 0.603
Diastolic BP, mmHg 74 ± 9 81 ± 16 77 ± 12 0.178
Heart rate, beats/min 74 ± 11 81 ± 19§ 70 ± 17 0.016
Body surface area, m22 1.80 ± 0.25 1.99 ± 0.30†§ 1.85 ± 0.24 0.027
NYHA classes
 I–II% 9 (43%) 29 (50%) 0.575
 III–IV% 12 (57%) 29 (50%)
Laboratory characteristics
 Hemoglobin, g/L 146 ± 9 148 ± 17§ 140 ± 16 0.039
 Scr, mmol/L 78 ± 16 85 ± 19 83 ± 17 0.775
 Baseline NT-proBNP, ng/l 69 (49,78) 1818 (817,5151) 1598 (739,3662) 0.450
 Follow-up NT-proBNP, ng/l 69 (22,131)§ 880 (286,1905) < 0.001
Electrocardiogram variables
 QRS duration, ms 87 ± 7 91 ± 15 99 ± 23 0.103
Baseline CMR parameters
 LVMI, g/m2 54 ± 10 81 ± 21 87 ± 28 0.293
 LVEDVI, ml/m22 68 ± 11 129 ± 29 140 ± 44 0.228
 LVESVI, ml/m2 29 ± 6 94 ± 26 106 ± 36 0.119
 LVSVI, ml/m2 40 ± 12 35 ± 9 34 ± 13 0.695
 LVEF, % 58 ± 5 28 ± 7 25 ± 7 0.080
 LVCI, L/min/m2 2.94 ± 0.74 2.80 ± 0.87 2.45 ± 0.93 0.131
 RVEF, % 54 ± 6 41 ± 6 42 ± 9 0.613
 LGE, +% (visual) 5 (24%) 24 (41%) 0.152
 LGE quantitative, 2 SD% 24.8 ± 13.0 28.1 ± 16.7 0.415
 LGE quantitative, 4 SD% 8.8 (4.2,17.3) 12.3 (2.9,21.1) 0.842
 LGE quantitative, 6 SD% 3.5 (1.2,9.0) 5.2 (0.7,11.4) 0.868
Follow-up CMR parameters
 LVMI, g/m2 66 ± 15§ 84 ± 31 0.014
 LVEDVI, ml/m2 79 ± 18§ 118 ± 37 < 0.001
 LVESVI, ml/m2 34 ± 10§ 81 ± 32 < 0.001
 LVSVI, ml/m2 45 ± 9 38 ± 20 0.123
 LVEF, % 57 ± 5§ 31 ± 10 < 0.001
 LVCI, L/min/m2 3.26 ± 0.60§ 2.64 ± 1.35 0.047
 RVEF, % 48 ± 5 46 ± 9 0.094
Medications
 ACEI/ARB, % 20 (95%) 53 (91%) 0.567
 Beta-blocker, % 21 (100%) 57 (98%) 0.545
 Spironolactone, % 18 (86%) 52 (90%) 0.626
 Diuretics, % 18 (86%) 52 (90%) 0.626
 Digoxin, % 4 (19%) 6 (12%) 0.325
Comorbidities
 Diabetes mellitus, % 5 (24%) 13 (22%) 0.896
 Hypertension, % 11 (52%) 20 (34%) 0.304
  1. BP blood pressure, NYHA New York Heart Association, Scr serum creatinine, NT-proBNP plasma N-terminal pro-B-type natriuretic peptide, LVMI left ventricular mass indexed to body surface area, LVEDVI left ventricular end diastolic volume indexed to body surface area, LVESVI left ventricular end systolic volume indexed to body surface area, LVSVI left ventricular stroke volume indexed to body surface area, LVEF left ventricular ejection fraction, LVCI left ventricular cardiac index, RVEF right ventricular ejection fraction, LGE late gadolinium enhancement, ACEI angiotensin-converting enzyme inhibitors, ARB, angiotensin receptor blocker
  2. P < 0.05 vs. control
  3. §P < 0.05 vs. Unrecovered NDCM, P values for baseline characteristics of the recovered and unrecovered patients were presented